+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID06495723

Study Evaluating the Safety and Effectiveness of LIS1 Antibody Treatment in Adults With Relapsed or Refractory Peripheral T Cells Lymphoma

Led by Xenothera SAS · Updated on 2026-08-20

54

Participants Needed

8

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying LIS1, a glyco-humanized polyclonal antibody drug, in adults with relapsed or refractory Peripheral T Cells Lymphoma PTCL. The trial aims to find the highest safe dose and recommended dose of LIS1, then evaluate its effectiveness and safety in certain PTCL subtypes. This phase 12, open-label study focuses on treatment options for patients whose disease has progressed after prior therapies. The trial has two parts Part 1 tests increasing doses of LIS1 2 mgkg, 4 mgkg, and 6 mgkg to determine the maximal tolerated dose or recommended dose for Part 2. In Part 2, participants receive LIS1 at the recommended dose to assess anti-tumor effects and further monitor safety. LIS1 is given intravenously, with dose adjustments based on findings from Part 1. Participants will undergo assessments including imaging to measure lesions, safety monitoring for treatment-related side effects for up to 60 days after the last dose, and pharmacokinetic testing at multiple timepoints during and after treatment cycles. The study tracks tumor response, survival, and other outcomes over several months after starting LIS1. Participants are monitored for at least three months for efficacy and up to a year for longer-term outcomes.

CONDITIONS

Brief Title

Polyspecific Antibodies in Lymphoproliferative T-cell Disorders

Research Team

F

Françoise SHNEIKER, MD

A

Alain BALEYDIER

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here